JP2008513508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008513508A5 JP2008513508A5 JP2007532665A JP2007532665A JP2008513508A5 JP 2008513508 A5 JP2008513508 A5 JP 2008513508A5 JP 2007532665 A JP2007532665 A JP 2007532665A JP 2007532665 A JP2007532665 A JP 2007532665A JP 2008513508 A5 JP2008513508 A5 JP 2008513508A5
- Authority
- JP
- Japan
- Prior art keywords
- substituent
- phenyl
- benzimidazol
- trifluoromethyl
- benzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001424 substituent group Chemical group 0.000 claims 493
- 125000000217 alkyl group Chemical group 0.000 claims 108
- 125000003710 aryl alkyl group Chemical group 0.000 claims 78
- 125000001072 heteroaryl group Chemical group 0.000 claims 65
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 57
- 125000000623 heterocyclic group Chemical group 0.000 claims 57
- 125000003342 alkenyl group Chemical group 0.000 claims 56
- -1 imidazo [4,5-b] pyridyl Chemical group 0.000 claims 50
- 125000003118 aryl group Chemical group 0.000 claims 45
- 125000000304 alkynyl group Chemical group 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 36
- 125000004093 cyano group Chemical group *C#N 0.000 claims 35
- 125000000753 cycloalkyl group Chemical group 0.000 claims 33
- 125000001188 haloalkyl group Chemical group 0.000 claims 25
- 125000004438 haloalkoxy group Chemical group 0.000 claims 23
- 125000005843 halogen group Chemical group 0.000 claims 23
- 238000000034 method Methods 0.000 claims 22
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 21
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 14
- 239000000651 prodrug Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 239000012453 solvate Substances 0.000 claims 14
- 150000001204 N-oxides Chemical class 0.000 claims 12
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 12
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 12
- 125000003107 substituted aryl group Chemical group 0.000 claims 12
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 12
- 125000004076 pyridyl group Chemical group 0.000 claims 10
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 8
- 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- JXQTVHIQYHIKJV-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)-5,6,7,8-tetrahydroindolizin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3CCCCC3=CC=2C(F)(F)F)=C1F JXQTVHIQYHIKJV-UHFFFAOYSA-N 0.000 claims 4
- RDLXPCACGCVSPE-UHFFFAOYSA-N 3,5-dichloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(Cl)=CC(Cl)=C1 RDLXPCACGCVSPE-UHFFFAOYSA-N 0.000 claims 4
- 102000004310 Ion Channels Human genes 0.000 claims 4
- 108090000862 Ion Channels Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- NYZSHNWJMOVYHJ-UHFFFAOYSA-N n-[(2,6-difluorophenyl)methyl]-4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]aniline Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NCC1=C(F)C=CC=C1F NYZSHNWJMOVYHJ-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 210000002865 immune cell Anatomy 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 125000000547 substituted alkyl group Chemical group 0.000 claims 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- NDHILZHKJYRCNN-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-3-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]urea Chemical compound FC1=CC=C(F)C(NC(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1 NDHILZHKJYRCNN-UHFFFAOYSA-N 0.000 claims 2
- GVBBXQKANCRVLH-UHFFFAOYSA-N 1-(2,5-difluorophenyl)-3-[6-[2-(trifluoromethyl)benzimidazol-1-yl]pyridin-3-yl]thiourea Chemical compound FC1=CC=C(F)C(NC(=S)NC=2C=NC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1 GVBBXQKANCRVLH-UHFFFAOYSA-N 0.000 claims 2
- LZOPTSHTAYYRSR-UHFFFAOYSA-N 2,3,4,5,6-pentafluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F LZOPTSHTAYYRSR-UHFFFAOYSA-N 0.000 claims 2
- XNVIGFYIEMIGKA-UHFFFAOYSA-N 2,3,4,5-tetrafluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(F)C(F)=C1F XNVIGFYIEMIGKA-UHFFFAOYSA-N 0.000 claims 2
- GICUSOPCJYWPHT-UHFFFAOYSA-N 2,3,4-trifluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(F)C(F)=C1F GICUSOPCJYWPHT-UHFFFAOYSA-N 0.000 claims 2
- QVFINXWCWBWOIK-UHFFFAOYSA-N 2,3,5-trifluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(F)=CC(F)=C1F QVFINXWCWBWOIK-UHFFFAOYSA-N 0.000 claims 2
- YQNHUFQCSKLAQP-UHFFFAOYSA-N 2,3,6-trifluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC(F)=C1F YQNHUFQCSKLAQP-UHFFFAOYSA-N 0.000 claims 2
- YAORPEGMKMDMRA-UHFFFAOYSA-N 2,3-dichloro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(Cl)=C1Cl YAORPEGMKMDMRA-UHFFFAOYSA-N 0.000 claims 2
- DZMKYTWSNMTCKO-UHFFFAOYSA-N 2,3-difluoro-n-[2-[2-(trifluoromethyl)benzimidazol-1-yl]pyridin-3-yl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C(=NC=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1F DZMKYTWSNMTCKO-UHFFFAOYSA-N 0.000 claims 2
- SJYDPDQXLCEMTM-UHFFFAOYSA-N 2,3-difluoro-n-[2-methyl-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound CC1=CC(N2C3=CC=CC=C3N=C2C(F)(F)F)=CC=C1NC(=O)C1=CC=CC(F)=C1F SJYDPDQXLCEMTM-UHFFFAOYSA-N 0.000 claims 2
- USHXWCFLWKHXCT-UHFFFAOYSA-N 2,3-difluoro-n-[3-methyl-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound C=1C=C(N2C3=CC=CC=C3N=C2C(F)(F)F)C(C)=CC=1NC(=O)C1=CC=CC(F)=C1F USHXWCFLWKHXCT-UHFFFAOYSA-N 0.000 claims 2
- WLTVMYFIMILLEK-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-iodobenzimidazol-1-yl)phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2I)=C1F WLTVMYFIMILLEK-UHFFFAOYSA-N 0.000 claims 2
- BNWFPUUMEPWACP-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-methylbenzimidazol-1-yl)phenyl]benzamide Chemical compound CC1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F BNWFPUUMEPWACP-UHFFFAOYSA-N 0.000 claims 2
- ZLXZGMSSHOAYQU-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-methylsulfanylbenzimidazol-1-yl)phenyl]benzamide Chemical compound CSC1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F ZLXZGMSSHOAYQU-UHFFFAOYSA-N 0.000 claims 2
- CABLTRGIQPFHIH-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-methylsulfinylbenzimidazol-1-yl)phenyl]benzamide Chemical compound CS(=O)C1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F CABLTRGIQPFHIH-UHFFFAOYSA-N 0.000 claims 2
- OHCMLEBTCDKRNK-UHFFFAOYSA-N 2,3-difluoro-n-[4-(2-propan-2-ylbenzimidazol-1-yl)phenyl]benzamide Chemical compound CC(C)C1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F OHCMLEBTCDKRNK-UHFFFAOYSA-N 0.000 claims 2
- BIQYZPDBEJUQGM-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzenecarbothioamide Chemical compound FC1=CC=CC(C(=S)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1F BIQYZPDBEJUQGM-UHFFFAOYSA-N 0.000 claims 2
- AQUYHDDKQMGPMS-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzenesulfonamide Chemical compound FC1=CC=CC(S(=O)(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1F AQUYHDDKQMGPMS-UHFFFAOYSA-N 0.000 claims 2
- UUQRYBZFXIXZPR-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)C=2N3C=CC=CC3=NC=2C(F)(F)F)=C1F UUQRYBZFXIXZPR-UHFFFAOYSA-N 0.000 claims 2
- YDVJLKAAQWIUBE-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)imidazo[4,5-b]pyridin-3-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=NC=CC=C3N=C2C(F)(F)F)=C1F YDVJLKAAQWIUBE-UHFFFAOYSA-N 0.000 claims 2
- KXEPQFRTQMIREX-UHFFFAOYSA-N 2,3-difluoro-n-[4-[2-(trifluoromethyl)imidazo[4,5-c]pyridin-1-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=NC=C3N=C2C(F)(F)F)=C1F KXEPQFRTQMIREX-UHFFFAOYSA-N 0.000 claims 2
- ADJJXDPCIXFJKO-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-hydroxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(O)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F ADJJXDPCIXFJKO-UHFFFAOYSA-N 0.000 claims 2
- IJASKOMAOIVHIT-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F IJASKOMAOIVHIT-UHFFFAOYSA-N 0.000 claims 2
- AZKCDWJDXNFRFR-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-methylsulfonyl-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(S(=O)(=O)C)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F AZKCDWJDXNFRFR-UHFFFAOYSA-N 0.000 claims 2
- XUPJMGITIFTAHP-UHFFFAOYSA-N 2,3-difluoro-n-[4-[6-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound C12=CC(OC)=CC=C2N=C(C(F)(F)F)N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F XUPJMGITIFTAHP-UHFFFAOYSA-N 0.000 claims 2
- RSZDQZYUWZZSBT-UHFFFAOYSA-N 2,4,6-trichloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=C(Cl)C=C(Cl)C=C1Cl RSZDQZYUWZZSBT-UHFFFAOYSA-N 0.000 claims 2
- JLXUMJXSSXGGLJ-UHFFFAOYSA-N 2,4-dichloro-5-fluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(F)=C(Cl)C=C1Cl JLXUMJXSSXGGLJ-UHFFFAOYSA-N 0.000 claims 2
- WTZBHFYQOCSDGG-UHFFFAOYSA-N 2,4-difluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC1=CC(F)=CC=C1C(=O)NC1=CC=C(N2C3=CC=CC=C3N=C2C(F)(F)F)C=C1 WTZBHFYQOCSDGG-UHFFFAOYSA-N 0.000 claims 2
- IDSYGRUNOOYCMV-UHFFFAOYSA-N 2,4-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(F)C=C1F IDSYGRUNOOYCMV-UHFFFAOYSA-N 0.000 claims 2
- IKKTUYBOEPABSN-UHFFFAOYSA-N 2,5-difluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1 IKKTUYBOEPABSN-UHFFFAOYSA-N 0.000 claims 2
- STWIJCLVZQFIDV-UHFFFAOYSA-N 2,5-difluoro-n-[4-[2-(trifluoromethyl)imidazo[4,5-b]pyridin-3-yl]phenyl]benzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=CC(=CC=2)N2C3=NC=CC=C3N=C2C(F)(F)F)=C1 STWIJCLVZQFIDV-UHFFFAOYSA-N 0.000 claims 2
- IWWVMQDFYQWEQQ-UHFFFAOYSA-N 2,5-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(F)=CC=C1F IWWVMQDFYQWEQQ-UHFFFAOYSA-N 0.000 claims 2
- IOLCOEXDLYSMMH-UHFFFAOYSA-N 2,5-difluoro-n-[6-[2-(trifluoromethyl)benzimidazol-1-yl]pyridin-3-yl]benzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=NC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1 IOLCOEXDLYSMMH-UHFFFAOYSA-N 0.000 claims 2
- WJONHQVDSQWGHO-UHFFFAOYSA-N 2,5-dimethoxy-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound COC1=CC=C(OC)C(C(=O)NC=2C=CC(=CC=2)N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)=C1 WJONHQVDSQWGHO-UHFFFAOYSA-N 0.000 claims 2
- WNJOWINYIFIHOJ-UHFFFAOYSA-N 2,6-dichloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=C(Cl)C=CC=C1Cl WNJOWINYIFIHOJ-UHFFFAOYSA-N 0.000 claims 2
- USRRTEKABQQVHS-UHFFFAOYSA-N 2,6-difluoro-3-iodo-n-[4-(5-methoxybenzimidazol-1-yl)phenyl]benzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC(I)=C1F USRRTEKABQQVHS-UHFFFAOYSA-N 0.000 claims 2
- BCLYFBJNROCIER-UHFFFAOYSA-N 2,6-difluoro-3-iodo-n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]benzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC(I)=C1F BCLYFBJNROCIER-UHFFFAOYSA-N 0.000 claims 2
- ASWDNJQDLYNLJP-UHFFFAOYSA-N 2,6-difluoro-3-iodo-n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]benzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC(I)=C1F ASWDNJQDLYNLJP-UHFFFAOYSA-N 0.000 claims 2
- LHHBWOICJSOJHZ-UHFFFAOYSA-N 2-(4-methoxyphenyl)-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)C=C1 LHHBWOICJSOJHZ-UHFFFAOYSA-N 0.000 claims 2
- CBIFSJNERXQRQW-UHFFFAOYSA-N 2-bromo-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1Br CBIFSJNERXQRQW-UHFFFAOYSA-N 0.000 claims 2
- HRUVLMPXLGXCGM-UHFFFAOYSA-N 2-chloro-n-[4-(5-methoxybenzimidazol-1-yl)phenyl]benzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1Cl HRUVLMPXLGXCGM-UHFFFAOYSA-N 0.000 claims 2
- IHMMICRQERCDJR-UHFFFAOYSA-N 2-chloro-n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]benzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1Cl IHMMICRQERCDJR-UHFFFAOYSA-N 0.000 claims 2
- FZBMTGURFDLPDN-UHFFFAOYSA-N 2-chloro-n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]benzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1Cl FZBMTGURFDLPDN-UHFFFAOYSA-N 0.000 claims 2
- SXQPAHAFCYNFLY-UHFFFAOYSA-N 2-chloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1Cl SXQPAHAFCYNFLY-UHFFFAOYSA-N 0.000 claims 2
- NOCCHZQVBIVCQW-UHFFFAOYSA-N 2-ethyl-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]hexanamide Chemical compound C1=CC(NC(=O)C(CC)CCCC)=CC=C1N1C2=CC=C(OC)C=C2N=C1C(F)(F)F NOCCHZQVBIVCQW-UHFFFAOYSA-N 0.000 claims 2
- NFDPCECSLSDDDY-UHFFFAOYSA-N 2-fluoro-n-[4-(5-methoxybenzimidazol-1-yl)phenyl]pyridine-4-carboxamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=NC(F)=C1 NFDPCECSLSDDDY-UHFFFAOYSA-N 0.000 claims 2
- GJEVIIPAENUIBN-UHFFFAOYSA-N 2-iodo-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1I GJEVIIPAENUIBN-UHFFFAOYSA-N 0.000 claims 2
- STYFOCUGOOYSHW-UHFFFAOYSA-N 2-methoxy-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1OC STYFOCUGOOYSHW-UHFFFAOYSA-N 0.000 claims 2
- NVVCPKOGHZWTJA-UHFFFAOYSA-N 2-methyl-n-[4-[2-(trifluoromethyl)-5,6,7,8-tetrahydroindolizin-3-yl]phenyl]benzamide Chemical compound CC1=CC=CC=C1C(=O)NC1=CC=C(C=2N3CCCCC3=CC=2C(F)(F)F)C=C1 NVVCPKOGHZWTJA-UHFFFAOYSA-N 0.000 claims 2
- WTKDONGBLLBOCY-UHFFFAOYSA-N 3,4-difluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(F)C(F)=C1 WTKDONGBLLBOCY-UHFFFAOYSA-N 0.000 claims 2
- OWCSBRYQRKXOIM-UHFFFAOYSA-N 3-amino-2,5,6-trifluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound NC1=CC(F)=C(F)C(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1F OWCSBRYQRKXOIM-UHFFFAOYSA-N 0.000 claims 2
- AAMSWDUSPQCVQZ-UHFFFAOYSA-N 3-bromo-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(Br)=C1 AAMSWDUSPQCVQZ-UHFFFAOYSA-N 0.000 claims 2
- HIKWCBVXIGPBHT-UHFFFAOYSA-N 3-chloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(Cl)=C1 HIKWCBVXIGPBHT-UHFFFAOYSA-N 0.000 claims 2
- BDLADPYJIMQNIB-UHFFFAOYSA-N 3-cyano-n-[4-(5-methoxybenzimidazol-1-yl)phenyl]benzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(C#N)=C1 BDLADPYJIMQNIB-UHFFFAOYSA-N 0.000 claims 2
- JRMPXPMAPQSQJW-UHFFFAOYSA-N 3-cyano-n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]benzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=CC(C#N)=C1 JRMPXPMAPQSQJW-UHFFFAOYSA-N 0.000 claims 2
- UVRZLVLNHWDKBX-UHFFFAOYSA-N 3-cyano-n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]benzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC(C#N)=C1 UVRZLVLNHWDKBX-UHFFFAOYSA-N 0.000 claims 2
- CMVWZNHPMLRUGI-UHFFFAOYSA-N 3-cyano-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(C#N)=C1 CMVWZNHPMLRUGI-UHFFFAOYSA-N 0.000 claims 2
- XYNBURGZOXHMRN-UHFFFAOYSA-N 3-fluoro-n-[4-(5-methoxybenzimidazol-1-yl)phenyl]-2-methylbenzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1C XYNBURGZOXHMRN-UHFFFAOYSA-N 0.000 claims 2
- XLNFCFCONHYRHB-UHFFFAOYSA-N 3-fluoro-n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]-2-methylbenzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1C XLNFCFCONHYRHB-UHFFFAOYSA-N 0.000 claims 2
- ARMLQESKISZKKL-UHFFFAOYSA-N 3-fluoro-n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]-2-methylbenzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1C ARMLQESKISZKKL-UHFFFAOYSA-N 0.000 claims 2
- AICXAWARARRAFX-UHFFFAOYSA-N 3-fluoro-n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]pyridine-4-carboxamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F AICXAWARARRAFX-UHFFFAOYSA-N 0.000 claims 2
- WCRFUXPDXXQZEO-UHFFFAOYSA-N 3-fluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]pyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(N2C3=CC=CC=C3N=C2C(F)(F)F)C=C1 WCRFUXPDXXQZEO-UHFFFAOYSA-N 0.000 claims 2
- RSRWRWVKRKWMCQ-UHFFFAOYSA-N 3-fluoro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]pyridine-4-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F RSRWRWVKRKWMCQ-UHFFFAOYSA-N 0.000 claims 2
- IVXIUBFPDOSNGA-UHFFFAOYSA-N 3-methoxy-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound COC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)=C1 IVXIUBFPDOSNGA-UHFFFAOYSA-N 0.000 claims 2
- JNTGUFDAGCIKBX-UHFFFAOYSA-N 4-amino-2,3-difluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC1=C(F)C(N)=CC=C1C(=O)NC1=CC=C(N2C3=CC=CC=C3N=C2C(F)(F)F)C=C1 JNTGUFDAGCIKBX-UHFFFAOYSA-N 0.000 claims 2
- FWZQVEATVJWESW-UHFFFAOYSA-N 4-bromo-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(Br)C=C1 FWZQVEATVJWESW-UHFFFAOYSA-N 0.000 claims 2
- YQVDJPVIPLKBPC-UHFFFAOYSA-N 4-butyl-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound C1=CC(CCCC)=CC=C1C(=O)NC1=CC=C(N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)C=C1 YQVDJPVIPLKBPC-UHFFFAOYSA-N 0.000 claims 2
- RDFFDCMIXYGIBG-UHFFFAOYSA-N 4-chloro-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(Cl)C=C1 RDFFDCMIXYGIBG-UHFFFAOYSA-N 0.000 claims 2
- MJJFLZLCLWGIMG-UHFFFAOYSA-N 4-cyano-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(C#N)C=C1 MJJFLZLCLWGIMG-UHFFFAOYSA-N 0.000 claims 2
- ZKGPFJXFHBRRMI-UHFFFAOYSA-N 4-ethyl-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound C1=CC(CC)=CC=C1C(=O)NC1=CC=C(N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)C=C1 ZKGPFJXFHBRRMI-UHFFFAOYSA-N 0.000 claims 2
- BFGKZORLMMMUKV-UHFFFAOYSA-N 4-iodo-n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(I)C=C1 BFGKZORLMMMUKV-UHFFFAOYSA-N 0.000 claims 2
- WDVDYJFNOMTNCU-UHFFFAOYSA-N 4-methyl-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1C WDVDYJFNOMTNCU-UHFFFAOYSA-N 0.000 claims 2
- LKYACNKBONMDEN-UHFFFAOYSA-N 4-methyl-n-[4-[2-(trifluoromethyl)imidazo[4,5-b]pyridin-3-yl]phenyl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=CC(=CC=2)N2C3=NC=CC=C3N=C2C(F)(F)F)=C1C LKYACNKBONMDEN-UHFFFAOYSA-N 0.000 claims 2
- ANAUKNJECKLZMN-UHFFFAOYSA-N 4-methyl-n-[6-[2-(trifluoromethyl)benzimidazol-1-yl]pyridin-3-yl]thiadiazole-5-carboxamide Chemical compound N1=NSC(C(=O)NC=2C=NC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1C ANAUKNJECKLZMN-UHFFFAOYSA-N 0.000 claims 2
- NHHQOYLPBUYHQU-UHFFFAOYSA-N 4-methylthiadiazole-5-carboxylic acid Chemical compound CC=1N=NSC=1C(O)=O NHHQOYLPBUYHQU-UHFFFAOYSA-N 0.000 claims 2
- TVOWKMJJUHYDDV-UHFFFAOYSA-N 6-chloro-6-fluoro-n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]cyclohexa-2,4-diene-1-carboxamide Chemical compound FC(F)(F)C1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1C=CC=CC1(F)Cl TVOWKMJJUHYDDV-UHFFFAOYSA-N 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- CDMAYTRBBUGRLV-UHFFFAOYSA-N [1-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)benzimidazol-5-yl] acetate Chemical compound FC(F)(F)C1=NC2=CC(OC(=O)C)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F CDMAYTRBBUGRLV-UHFFFAOYSA-N 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- FSJFCTWARUQVHX-UHFFFAOYSA-N ethyl 4-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]anilino]-4-oxobutanoate Chemical compound C1=CC(NC(=O)CCC(=O)OCC)=CC=C1N1C2=CC=C(OC)C=C2N=C1C(F)(F)F FSJFCTWARUQVHX-UHFFFAOYSA-N 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- QHGPRISBGALTTN-UHFFFAOYSA-N methyl 1-[4-[(2,3-difluorobenzoyl)amino]phenyl]-2-(trifluoromethyl)benzimidazole-5-carboxylate Chemical compound FC(F)(F)C1=NC2=CC(C(=O)OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F QHGPRISBGALTTN-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- WHMXJMHLCRQWCR-UHFFFAOYSA-N n-(2,3-difluorophenyl)-4-[2-(trifluoromethyl)benzimidazol-1-yl]benzamide Chemical compound FC1=CC=CC(NC(=O)C=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1F WHMXJMHLCRQWCR-UHFFFAOYSA-N 0.000 claims 2
- KXGKCBJPVVVOCQ-UHFFFAOYSA-N n-[2-chloro-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C(=CC(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)Cl)=C1F KXGKCBJPVVVOCQ-UHFFFAOYSA-N 0.000 claims 2
- JOVWONYNEYUPHQ-UHFFFAOYSA-N n-[3-acetamido-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound C=1C=C(N2C3=CC=CC=C3N=C2C(F)(F)F)C(NC(=O)C)=CC=1NC(=O)C1=CC=CC(F)=C1F JOVWONYNEYUPHQ-UHFFFAOYSA-N 0.000 claims 2
- QFTRIIOTZXYYLX-UHFFFAOYSA-N n-[3-chloro-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,5-difluorobenzamide Chemical compound FC1=CC=C(F)C(C(=O)NC=2C=C(Cl)C(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)=C1 QFTRIIOTZXYYLX-UHFFFAOYSA-N 0.000 claims 2
- GTMFLBLMEMCWHC-UHFFFAOYSA-N n-[4-(2-bromobenzimidazol-1-yl)phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2Br)=C1F GTMFLBLMEMCWHC-UHFFFAOYSA-N 0.000 claims 2
- QZBOJOYETLHECD-UHFFFAOYSA-N n-[4-(2-chlorobenzimidazol-1-yl)phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2Cl)=C1F QZBOJOYETLHECD-UHFFFAOYSA-N 0.000 claims 2
- KYOODLYONMDKGC-UHFFFAOYSA-N n-[4-(5-methoxybenzimidazol-1-yl)phenyl]-2-methylbenzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C KYOODLYONMDKGC-UHFFFAOYSA-N 0.000 claims 2
- BHIYJVKYNIOSIN-UHFFFAOYSA-N n-[4-(5-methoxybenzimidazol-1-yl)phenyl]-2-nitrobenzamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1[N+]([O-])=O BHIYJVKYNIOSIN-UHFFFAOYSA-N 0.000 claims 2
- IPHUDOSHXWAEBX-UHFFFAOYSA-N n-[4-(5-methoxybenzimidazol-1-yl)phenyl]cyclohexanecarboxamide Chemical compound C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1CCCCC1 IPHUDOSHXWAEBX-UHFFFAOYSA-N 0.000 claims 2
- GXBGEIZGYCDYAR-UHFFFAOYSA-N n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]-2-methylbenzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C GXBGEIZGYCDYAR-UHFFFAOYSA-N 0.000 claims 2
- ZXKZHDWJXOIQLF-UHFFFAOYSA-N n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]-2-nitrobenzamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1[N+]([O-])=O ZXKZHDWJXOIQLF-UHFFFAOYSA-N 0.000 claims 2
- FZVYGTPEDRUTCA-UHFFFAOYSA-N n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C FZVYGTPEDRUTCA-UHFFFAOYSA-N 0.000 claims 2
- ZOXOIXFJMFEIMC-UHFFFAOYSA-N n-[4-(7-methoxy-5,6,7,8-tetrahydroindolizin-3-yl)phenyl]cyclohexanecarboxamide Chemical compound C1C(OC)CCN2C1=CC=C2C(C=C1)=CC=C1NC(=O)C1CCCCC1 ZOXOIXFJMFEIMC-UHFFFAOYSA-N 0.000 claims 2
- XMNQIGQKFNMBSO-UHFFFAOYSA-N n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]-2-methylbenzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1C XMNQIGQKFNMBSO-UHFFFAOYSA-N 0.000 claims 2
- LKNQOBSBAYRHJL-UHFFFAOYSA-N n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]-3-nitrobenzamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1=CC=CC([N+]([O-])=O)=C1 LKNQOBSBAYRHJL-UHFFFAOYSA-N 0.000 claims 2
- UUUOZUQSKQAIMG-UHFFFAOYSA-N n-[4-(7-methoxyimidazo[1,2-a]pyridin-3-yl)phenyl]cyclohexanecarboxamide Chemical compound C=1N=C2C=C(OC)C=CN2C=1C(C=C1)=CC=C1NC(=O)C1CCCCC1 UUUOZUQSKQAIMG-UHFFFAOYSA-N 0.000 claims 2
- SJZYJWXYKJZBSI-UHFFFAOYSA-N n-[4-(benzimidazol-1-yl)phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=CC=C3N=C2)=C1F SJZYJWXYKJZBSI-UHFFFAOYSA-N 0.000 claims 2
- SHRJYRZYIJOWLX-UHFFFAOYSA-N n-[4-[2,5-bis(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=C(C=C3N=C2C(F)(F)F)C(F)(F)F)=C1F SHRJYRZYIJOWLX-UHFFFAOYSA-N 0.000 claims 2
- UATOZHQHXWVVTJ-UHFFFAOYSA-N n-[4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=NC2=CC=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CN=C1 UATOZHQHXWVVTJ-UHFFFAOYSA-N 0.000 claims 2
- INTIFULFQYVKPA-UHFFFAOYSA-N n-[4-[5,6-dihydroxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound C1=2C=C(O)C(O)=CC=2N=C(C(F)(F)F)N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F INTIFULFQYVKPA-UHFFFAOYSA-N 0.000 claims 2
- CVWHXYXRTDDJIW-UHFFFAOYSA-N n-[4-[5,6-dimethoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound C1=2C=C(OC)C(OC)=CC=2N=C(C(F)(F)F)N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F CVWHXYXRTDDJIW-UHFFFAOYSA-N 0.000 claims 2
- VAPNHNVXNFCCKD-UHFFFAOYSA-N n-[4-[5,6-dimethyl-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound C1=2C=C(C)C(C)=CC=2N=C(C(F)(F)F)N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F VAPNHNVXNFCCKD-UHFFFAOYSA-N 0.000 claims 2
- NESIOEBTWSZNNO-UHFFFAOYSA-N n-[4-[5-(1,3-dioxoisoindol-2-yl)-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC=C(C=C3N=C2C(F)(F)F)N2C(C3=CC=CC=C3C2=O)=O)=C1F NESIOEBTWSZNNO-UHFFFAOYSA-N 0.000 claims 2
- MRIZYVURCDALJG-UHFFFAOYSA-N n-[4-[5-(5-tert-butyl-1,3-oxazol-2-yl)-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,5-difluorobenzamide Chemical compound O1C(C(C)(C)C)=CN=C1C1=CC=C(N(C(=N2)C(F)(F)F)C=3C=CC(NC(=O)C=4C(=CC=C(F)C=4)F)=CC=3)C2=C1 MRIZYVURCDALJG-UHFFFAOYSA-N 0.000 claims 2
- WTWSFUCCIXTQCS-UHFFFAOYSA-N n-[4-[5-(5-tert-butyl-1,3-oxazol-2-yl)-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]furan-2-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1C1=CC=C(N(C(=N2)C(F)(F)F)C=3C=CC(NC(=O)C=4OC=CC=4)=CC=3)C2=C1 WTWSFUCCIXTQCS-UHFFFAOYSA-N 0.000 claims 2
- WASSJGCJFVHDQE-UHFFFAOYSA-N n-[4-[5-acetyl-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC(F)(F)C1=NC2=CC(C(=O)C)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F WASSJGCJFVHDQE-UHFFFAOYSA-N 0.000 claims 2
- GXLINRJNBQPSQQ-UHFFFAOYSA-N n-[4-[5-amino-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC(F)(F)C1=NC2=CC(N)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F GXLINRJNBQPSQQ-UHFFFAOYSA-N 0.000 claims 2
- QMRRNDPWMBMPAX-UHFFFAOYSA-N n-[4-[5-chloro-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-n-(2,3-difluorobenzoyl)-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)N(C(=O)C=2C(=C(F)C=CC=2)F)C=2C=CC(=CC=2)N2C3=CC=C(Cl)C=C3N=C2C(F)(F)F)=C1F QMRRNDPWMBMPAX-UHFFFAOYSA-N 0.000 claims 2
- LTSOXDGYGWOFSD-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-1,3-benzodioxole-5-carboxamide Chemical compound C1=C2OCOC2=CC(C(=O)NC2=CC=C(C=C2)N2C3=CC=C(C=C3N=C2C(F)(F)F)OC)=C1 LTSOXDGYGWOFSD-UHFFFAOYSA-N 0.000 claims 2
- IMTCNFLWACKYSN-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-1-(2,2,2-trifluoroacetyl)pyrrolidine-2-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1CCCN1C(=O)C(F)(F)F IMTCNFLWACKYSN-UHFFFAOYSA-N 0.000 claims 2
- YWPBJNVRZCGYQF-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,5-bis(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC=C1C(F)(F)F YWPBJNVRZCGYQF-UHFFFAOYSA-N 0.000 claims 2
- NRZGVKRDMQOBTN-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2-phenylcyclopropane-1-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1CC1C1=CC=CC=C1 NRZGVKRDMQOBTN-UHFFFAOYSA-N 0.000 claims 2
- OXYSSMNPNAQGHL-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2-phenylmethoxyacetamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)COCC1=CC=CC=C1 OXYSSMNPNAQGHL-UHFFFAOYSA-N 0.000 claims 2
- RXBCUGVQHUIXDT-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2-phenylsulfanylacetamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)CSC1=CC=CC=C1 RXBCUGVQHUIXDT-UHFFFAOYSA-N 0.000 claims 2
- LWWUYLGTYCABBX-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LWWUYLGTYCABBX-UHFFFAOYSA-N 0.000 claims 2
- XAZVSFABUPAIJG-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3,5-dinitrobenzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 XAZVSFABUPAIJG-UHFFFAOYSA-N 0.000 claims 2
- DAAYMBSRUASHKV-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(C(F)(F)F)=C1 DAAYMBSRUASHKV-UHFFFAOYSA-N 0.000 claims 2
- WAEXLYVYNWWNNR-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3-methylbut-2-enamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C1=CC=C(NC(=O)C=C(C)C)C=C1 WAEXLYVYNWWNNR-UHFFFAOYSA-N 0.000 claims 2
- GXIUHRWIWGDWDP-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3-methylbutanamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C1=CC=C(NC(=O)CC(C)C)C=C1 GXIUHRWIWGDWDP-UHFFFAOYSA-N 0.000 claims 2
- DCVYKLJISKKYRS-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C DCVYKLJISKKYRS-UHFFFAOYSA-N 0.000 claims 2
- IKERPCKBHVZVBW-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-4-(trifluoromethyl)benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(C(F)(F)F)C=C1 IKERPCKBHVZVBW-UHFFFAOYSA-N 0.000 claims 2
- JBUBWSITIXZQBN-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-4-methylbenzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C(C)C=C1 JBUBWSITIXZQBN-UHFFFAOYSA-N 0.000 claims 2
- FORVYHNTDVWPLE-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-4-nitrobenzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=C([N+]([O-])=O)C=C1 FORVYHNTDVWPLE-UHFFFAOYSA-N 0.000 claims 2
- RWPNCJMQXJUUJH-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-4-phenylbenzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C(C=C1)=CC=C1C1=CC=CC=C1 RWPNCJMQXJUUJH-UHFFFAOYSA-N 0.000 claims 2
- JPFOMLZUWHZZBE-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-4-propylbenzamide Chemical compound C1=CC(CCC)=CC=C1C(=O)NC1=CC=C(N2C3=CC=C(OC)C=C3N=C2C(F)(F)F)C=C1 JPFOMLZUWHZZBE-UHFFFAOYSA-N 0.000 claims 2
- APVQDEABACHKCU-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC=C1 APVQDEABACHKCU-UHFFFAOYSA-N 0.000 claims 2
- QZTCCYZCNSQAFR-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1N1C2=CC=C(OC)C=C2N=C1C(F)(F)F QZTCCYZCNSQAFR-UHFFFAOYSA-N 0.000 claims 2
- QASLOEVGJNNAFR-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]cyclohexanecarboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1CCCCC1 QASLOEVGJNNAFR-UHFFFAOYSA-N 0.000 claims 2
- PADGSVTYKJKTQF-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]furan-2-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CO1 PADGSVTYKJKTQF-UHFFFAOYSA-N 0.000 claims 2
- NQQBZLPQZWTEFL-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]heptanamide Chemical compound C1=CC(NC(=O)CCCCCC)=CC=C1N1C2=CC=C(OC)C=C2N=C1C(F)(F)F NQQBZLPQZWTEFL-UHFFFAOYSA-N 0.000 claims 2
- LBZLQUKJYHDFIU-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(=O)NC3=CC=C(C=C3)N3C4=CC=C(C=C4N=C3C(F)(F)F)OC)=CC=CC2=C1 LBZLQUKJYHDFIU-UHFFFAOYSA-N 0.000 claims 2
- YECHOPNGZNETDR-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)NC3=CC=C(C=C3)N3C4=CC=C(C=C4N=C3C(F)(F)F)OC)=CC=C21 YECHOPNGZNETDR-UHFFFAOYSA-N 0.000 claims 2
- APANNDQZYKIMIG-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]prop-2-enamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C1=CC=C(NC(=O)C=C)C=C1 APANNDQZYKIMIG-UHFFFAOYSA-N 0.000 claims 2
- FYRNRVORBWZFPI-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]pyridine-4-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1 FYRNRVORBWZFPI-UHFFFAOYSA-N 0.000 claims 2
- VRHHJGSMXUUBBK-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]thiophene-2-carboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CS1 VRHHJGSMXUUBBK-UHFFFAOYSA-N 0.000 claims 2
- NWOUKSVJOGEHIJ-UHFFFAOYSA-N n-[4-[5-tert-butyl-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC(F)(F)C1=NC2=CC(C(C)(C)C)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F NWOUKSVJOGEHIJ-UHFFFAOYSA-N 0.000 claims 2
- RPTMFGCMSITHHJ-UHFFFAOYSA-N n-[4-[6-acetamido-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound C12=CC(NC(=O)C)=CC=C2N=C(C(F)(F)F)N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F RPTMFGCMSITHHJ-UHFFFAOYSA-N 0.000 claims 2
- GVBNYIUPEBKTGF-UHFFFAOYSA-N n-[4-[6-chloro-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-n-(2,3-difluorobenzoyl)-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)N(C(=O)C=2C(=C(F)C=CC=2)F)C=2C=CC(=CC=2)N2C3=CC(Cl)=CC=C3N=C2C(F)(F)F)=C1F GVBNYIUPEBKTGF-UHFFFAOYSA-N 0.000 claims 2
- JMQMKJQGSWHKCN-UHFFFAOYSA-N n-[4-[6-cyano-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=CC(=CC=2)N2C3=CC(=CC=C3N=C2C(F)(F)F)C#N)=C1F JMQMKJQGSWHKCN-UHFFFAOYSA-N 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- LVHCALKLRRZQMY-UHFFFAOYSA-N 2,3-difluoro-n-[3-(trifluoromethyl)-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=C(C(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)C(F)(F)F)=C1F LVHCALKLRRZQMY-UHFFFAOYSA-N 0.000 claims 1
- JYOVLBTVWVSVGF-UHFFFAOYSA-N 2,3-difluoro-n-[4-[5-propan-2-yloxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]benzamide Chemical compound FC(F)(F)C1=NC2=CC(OC(C)C)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1=CC=CC(F)=C1F JYOVLBTVWVSVGF-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000008822 Ankylosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 241000207892 Convolvulus Species 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 101000844504 Homo sapiens Transient receptor potential cation channel subfamily M member 4 Proteins 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 102000000743 Interleukin-5 Human genes 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 102000003618 TRPM4 Human genes 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 230000005931 immune cell recruitment Effects 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000004816 latex Substances 0.000 claims 1
- 229920000126 latex Polymers 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- BPYCTPJZQPURRX-UHFFFAOYSA-N n-[3-cyano-4-[2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound FC1=CC=CC(C(=O)NC=2C=C(C(=CC=2)N2C3=CC=CC=C3N=C2C(F)(F)F)C#N)=C1F BPYCTPJZQPURRX-UHFFFAOYSA-N 0.000 claims 1
- JLRJUMVQKKUTIH-UHFFFAOYSA-N n-[4-[5-(5-tert-butyl-1,3-oxazol-2-yl)-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]-2,3-difluorobenzamide Chemical compound O1C(C(C)(C)C)=CN=C1C1=CC=C(N(C(=N2)C(F)(F)F)C=3C=CC(NC(=O)C=4C(=C(F)C=CC=4)F)=CC=3)C2=C1 JLRJUMVQKKUTIH-UHFFFAOYSA-N 0.000 claims 1
- NJKDNRVPWMOOPB-UHFFFAOYSA-N n-[4-[5-methoxy-2-(trifluoromethyl)benzimidazol-1-yl]phenyl]cyclopentanecarboxamide Chemical compound FC(F)(F)C1=NC2=CC(OC)=CC=C2N1C(C=C1)=CC=C1NC(=O)C1CCCC1 NJKDNRVPWMOOPB-UHFFFAOYSA-N 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 *C(*1)=CC=C1I* Chemical compound *C(*1)=CC=C1I* 0.000 description 19
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61191304P | 2004-09-21 | 2004-09-21 | |
| PCT/US2005/033980 WO2006034402A2 (en) | 2004-09-21 | 2005-09-21 | Compounds for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008513508A JP2008513508A (ja) | 2008-05-01 |
| JP2008513508A5 true JP2008513508A5 (enExample) | 2008-11-13 |
Family
ID=36090672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007532665A Pending JP2008513508A (ja) | 2004-09-21 | 2005-09-21 | 炎症及び免疫に関連する用途に用いる化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US7709518B2 (enExample) |
| EP (1) | EP1809294A4 (enExample) |
| JP (1) | JP2008513508A (enExample) |
| KR (1) | KR20070057965A (enExample) |
| CN (1) | CN101083985A (enExample) |
| AU (1) | AU2005286701A1 (enExample) |
| BR (1) | BRPI0515546A (enExample) |
| CA (1) | CA2580852A1 (enExample) |
| IL (1) | IL182025A0 (enExample) |
| MX (1) | MX2007003342A (enExample) |
| TW (1) | TW200621232A (enExample) |
| WO (1) | WO2006034402A2 (enExample) |
| ZA (1) | ZA200702350B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070057965A (ko) * | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| AU2006208045B2 (en) | 2005-01-25 | 2012-08-30 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2006081389A1 (en) * | 2005-01-25 | 2006-08-03 | Synta Pharmaceuticals Corp. | Thiophene compounds for inflammation and immune-related uses |
| CA2640090A1 (en) * | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
| JP2009528273A (ja) * | 2006-01-25 | 2009-08-06 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連使用用の置換ビアリール化合物 |
| WO2007087443A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| AU2007211276B2 (en) * | 2006-01-31 | 2013-06-06 | Synta Pharmaceuticals Corp. | Pyridylphenyl compounds for inflammation and immune-related uses |
| CA2645434A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceutical Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
| CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| UA101611C2 (ru) | 2007-04-03 | 2013-04-25 | Аррей Байофарма Инк. | СОЕДИНЕНИЯ ИМИДАЗО[1,2-а]ПИРИДИНА КАК ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ РЕЦЕПТОРОВ |
| EP2152677A1 (en) * | 2007-05-03 | 2010-02-17 | NeuroSearch A/S | Acetamide derivatives as potassium channel modulators |
| US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
| RU2465272C2 (ru) | 2007-09-10 | 2012-10-27 | КалсиМедика, Инк. | Соединения, моделирующие внутриклеточный кальций |
| US8324219B2 (en) | 2007-09-20 | 2012-12-04 | Synta Pharmaceuticals Corp. | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
| GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
| US7868001B2 (en) * | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| WO2009076454A2 (en) * | 2007-12-12 | 2009-06-18 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| CA2734500A1 (en) | 2008-08-27 | 2010-03-11 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
| US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8143269B2 (en) * | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| US9545455B2 (en) * | 2009-04-29 | 2017-01-17 | Pravin K. Muniyappa | Device and method for the diagnosis of gastrointestinal allergy |
| US8618307B2 (en) * | 2009-09-16 | 2013-12-31 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN102803502B (zh) * | 2009-09-29 | 2019-06-04 | 宾夕法尼亚大学理事会 | 用于诊断和治疗脑炎或癫痫的方法 |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8809541B2 (en) * | 2010-08-25 | 2014-08-19 | Neopharm Co., Ltd. | Heterocyclic compound, and composition for treating inflammatory diseases using same |
| CN103180316A (zh) * | 2010-08-27 | 2013-06-26 | 钙医学公司 | 调节细胞内钙的化合物 |
| AP3341A (en) | 2010-10-30 | 2015-07-31 | Lupin Ltd | Oxazoline and isoxazoline derivatives as crac modulators |
| US9688492B2 (en) | 2011-03-10 | 2017-06-27 | Ksw Environmental, Llc | Method of reducing silicosis caused by inhalation of silica-containing proppant, such as silica sand and resin-coated silica sand, and apparatus therefor |
| WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2844655A1 (en) | 2012-05-02 | 2015-03-11 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| AU2013255441B2 (en) | 2012-05-02 | 2017-11-09 | Lupin Limited | Substituted pyrazole compounds as CRAC modulators |
| WO2014059333A1 (en) | 2012-10-12 | 2014-04-17 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| US9725463B2 (en) | 2013-06-21 | 2017-08-08 | Lupin Limited | Substituted heterocyclic compounds as CRAC modulators |
| EP3013810A1 (en) | 2013-06-24 | 2016-05-04 | Lupin Limited | Chromane and chromene derivatives and their use as crac modulators |
| EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
| US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| EA031201B1 (ru) | 2014-08-06 | 2018-11-30 | Пфайзер Инк. | Соединения имидазопиридазина |
| CN107207431B (zh) * | 2015-01-13 | 2021-02-09 | 维夫雷昂生物科学有限责任公司 | Ca2+释放激活的Ca2+(CRAC)通道的调节剂及其药物用途 |
| TWI771269B (zh) | 2015-02-27 | 2022-07-21 | 美商鈣系醫藥公司 | 胰腺炎治療 |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| ES2830447T3 (es) * | 2015-12-15 | 2021-06-03 | Univ Leland Stanford Junior | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación |
| JP2022508468A (ja) | 2018-09-14 | 2022-01-19 | ルヒゼン ファーマスティカルズ アクツィエンゲゼルシャフト | Ｃｒａｃ阻害剤およびコルチコステロイドを含む組成物ならびにそれらの使用方法 |
| EP3990458A4 (en) * | 2019-06-25 | 2025-01-08 | Sinopsee Therapeutics | LINKS TO THE TREATMENT OF CANCER |
| CN114206850B (zh) | 2019-09-25 | 2024-01-26 | 辰欣药业股份有限公司 | 作为crac抑制剂的2h-苯并吡喃衍生物 |
| US12486274B2 (en) | 2020-01-13 | 2025-12-02 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| CA3172249A1 (en) | 2020-03-20 | 2021-09-23 | Calcimedica, Inc. | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome |
| EP4221701A1 (en) * | 2020-09-30 | 2023-08-09 | FL2022-001, Inc. | Hsd17b13 inhibitors and uses thereof |
| JP7791898B2 (ja) | 2020-11-13 | 2025-12-24 | カルシメディカ，インク． | Ｃｒａｃチャネル阻害剤の合成の改善 |
| WO2025077671A1 (zh) * | 2023-10-09 | 2025-04-17 | 浙江海正药业股份有限公司 | 多取代芳基类衍生物及其制备方法和用途 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| JPS5799648A (en) * | 1980-12-13 | 1982-06-21 | Copyer Co Ltd | Electrophotographic receptor |
| NL8104104A (nl) * | 1981-09-04 | 1983-04-05 | Philips Nv | Distributiesysteem voor een lokaal fibernet. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8709448D0 (en) * | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| JP2663175B2 (ja) * | 1989-06-28 | 1997-10-15 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5025000A (en) * | 1990-03-02 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Phosphorus-containing HMG-CoA reductase inhibitor compounds |
| GB9010404D0 (en) | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5285305A (en) * | 1991-12-12 | 1994-02-08 | At & T Bell Laboratories | Optical communication network with passive monitoring |
| US5321541A (en) * | 1991-12-12 | 1994-06-14 | At&T Bell Laboratories | Passive optical communication network with broadband upgrade |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| GB9200245D0 (en) * | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
| US5322847A (en) * | 1992-11-05 | 1994-06-21 | Pfizer Inc. | Azabenzimidazoles in the treatment of asthma, arthritis and related diseases |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5440416A (en) * | 1993-02-24 | 1995-08-08 | At&T Corp. | Optical network comprising a compact wavelength-dividing component |
| DE4330959A1 (de) | 1993-09-09 | 1995-03-16 | Schering Ag | Neue Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5680234A (en) * | 1994-10-20 | 1997-10-21 | Lucent Technologies Inc. | Passive optical network with bi-directional optical spectral slicing and loop-back |
| US5579421A (en) * | 1995-11-21 | 1996-11-26 | Lucent Technologies Inc. | Optical integrated circuits and methods |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| US5926298A (en) * | 1996-08-30 | 1999-07-20 | Lucent Technologies Inc. | Optical multiplexer/demultiplexer having a broadcast port |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| GB9704587D0 (en) * | 1997-03-05 | 1997-04-23 | Fujitsu Ltd | Wavelength-division multiplexing in passive optical networks |
| US6163637A (en) * | 1997-04-28 | 2000-12-19 | Lucent Technologies Inc. | Chirped waveguide grating router as a splitter/router |
| ZA985247B (en) * | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| US6144472A (en) * | 1998-01-20 | 2000-11-07 | Lucent Technologies Inc. | Upgrading a power-splitting passive optical network using optical filtering |
| US6919366B2 (en) * | 1998-05-22 | 2005-07-19 | Avanir Pharmaceuticals | Benzimidazole derivatives as modulators of IgE |
| DE69924493T2 (de) * | 1998-07-02 | 2005-09-15 | Neurosearch A/S | Kaliumkanal-blockierende mittel |
| US6194447B1 (en) * | 1998-07-02 | 2001-02-27 | Neurosearch A/S | Bis (benzimidazole) derivatives serving as potassium blocking agents |
| EP1119568B1 (en) * | 1998-10-09 | 2004-02-18 | Janssen Pharmaceutica N.V. | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| IL128503A (en) | 1999-02-11 | 2003-07-06 | Eci Telecom Ltd | Wdm multiplexer |
| US6498876B1 (en) * | 1999-02-22 | 2002-12-24 | Alliance Fiber Optics Products, Inc. | Multi-port fiber optic device with v-groove ferrule |
| DE19935219A1 (de) * | 1999-07-27 | 2001-02-01 | Boehringer Ingelheim Pharma | Carbonsäureamide, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
| CZ2002961A3 (cs) * | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| US7386236B1 (en) * | 1999-09-27 | 2008-06-10 | Alloptic, Inc. | Multiple wavelength TDMA optical network |
| AU2277201A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Novel purines |
| US6396573B1 (en) | 2000-02-17 | 2002-05-28 | Fitel U.S.A. Corp. | System and method for optically testing broadcasting systems |
| US6767139B2 (en) | 2000-06-22 | 2004-07-27 | Avanex Corporation | Six-port optical package and method of manufacturing |
| FR2818059B1 (fr) * | 2000-12-07 | 2003-02-07 | Cit Alcatel | Dispositif de demultiplexage de bandes de frequences |
| US6797139B2 (en) * | 2001-03-19 | 2004-09-28 | Applera Corporation | Detection cell for guiding excitation light therein and method for using same |
| EP2048142A3 (en) | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| US20020196491A1 (en) * | 2001-06-25 | 2002-12-26 | Deng Kung Li | Passive optical network employing coarse wavelength division multiplexing and related methods |
| WO2003005025A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| US7529485B2 (en) * | 2001-07-05 | 2009-05-05 | Enablence Usa Fttx Networks, Inc. | Method and system for supporting multiple services with a subscriber optical interface located outside a subscriber's premises |
| IL161576A0 (en) | 2001-10-26 | 2004-09-27 | Aventis Pharma Inc | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| GB0206860D0 (en) | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| US20040001718A1 (en) * | 2002-06-26 | 2004-01-01 | Matthews Manyalibo Joseph | Course wavelength division multiplexed optical network |
| AU2003254177A1 (en) * | 2002-07-31 | 2004-02-16 | Smithkline Beecham Corporation | Substituted benzanilides as modulators of the ccr5 receptor |
| US6717025B1 (en) * | 2002-11-15 | 2004-04-06 | Exxonmobil Chemical Patents Inc | Process for removing oxygenates from an olefinic stream |
| WO2004054151A1 (fr) * | 2002-12-02 | 2004-06-24 | Ekinops | Procede de transmission synchrone longue distance par fibre optique |
| PE20040804A1 (es) * | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
| US7203422B2 (en) | 2002-12-26 | 2007-04-10 | Nippon Telegraph And Telephone Corporation | Optical network unit, wavelength splitter, and optical wavelength-division multiplexing access system |
| KR100532307B1 (ko) * | 2003-03-17 | 2005-11-29 | 삼성전자주식회사 | 방송, 통신 융합이 가능한 파장 분할 다중화 방식의수동형 광 가입자망 |
| JP3938924B2 (ja) * | 2003-06-18 | 2007-06-27 | 日本電信電話株式会社 | 光波長多重アクセスシステムおよび光ネットワークユニット |
| US20050129404A1 (en) * | 2003-12-10 | 2005-06-16 | Kim Byoung W. | Apparatus for providing broadcasting service through overlay structure in WDM-PON |
| US7245829B1 (en) * | 2004-01-12 | 2007-07-17 | Nortel Networks Limited | Architecture for dynamic connectivity in an edge photonic network architecture |
| US20050175343A1 (en) * | 2004-02-03 | 2005-08-11 | Utstarcom, Inc. | System and apparatus for a carrier class WDM PON for increased split number and bandwidth |
| US20050175344A1 (en) * | 2004-02-06 | 2005-08-11 | Utstarcom, Inc. | System and apparatus for a carrier class WDM PON accommodating multiple services or protocols |
| US7689073B2 (en) * | 2004-02-17 | 2010-03-30 | Alcatel-Lucent Usa Inc. | 1×N wavelength selective switch |
| WO2005091752A2 (en) * | 2004-03-25 | 2005-10-06 | Synta Pharmaceuticals Corp. | Acrylonitrile derivatives for inflammation and immune-related uses |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| JP2008517974A (ja) | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| KR100678256B1 (ko) * | 2005-01-12 | 2007-02-02 | 삼성전자주식회사 | 파장 분할다중 방식 수동형 광 가입자 망 |
| WO2006102645A1 (en) * | 2005-03-24 | 2006-09-28 | Janssen Pharmaceutica, N.V. | Biaryl derived amide modulators of vanilloid vr1 receptor |
| US7684705B2 (en) * | 2005-10-20 | 2010-03-23 | Fujitsu Limited | Distribution node for a wavelength-sharing network |
| US8023823B2 (en) * | 2005-10-20 | 2011-09-20 | Fujitsu Limited | System and method for transmitting upstream traffic in an optical network |
| US7653309B2 (en) * | 2005-10-20 | 2010-01-26 | Fujitsu Limited | System and method for distributing traffic in an optical network |
| US7684706B2 (en) * | 2005-10-20 | 2010-03-23 | Fujitsu Limited | System and method for traffic distribution in an optical network |
| US7499651B2 (en) * | 2005-10-20 | 2009-03-03 | Fujitsu Limited | Upgradeable passive optical network |
| US7546036B2 (en) * | 2005-10-20 | 2009-06-09 | Fujitsu Limited | Hybrid passive optical network using shared wavelengths |
| US7522838B2 (en) * | 2005-10-20 | 2009-04-21 | Fujitsu Limited | Distribution components for a wavelength-sharing network |
| US7603036B2 (en) | 2006-01-06 | 2009-10-13 | Fujitsu Limited | System and method for managing network components in a hybrid passive optical network |
| US8180223B2 (en) * | 2006-02-03 | 2012-05-15 | Fujitsu Limited | System and method for extending reach in a passive optical network |
| US7715719B2 (en) * | 2006-06-02 | 2010-05-11 | Fujitsu Limited | System and method for transmitting traffic in a plurality of passive optical networks |
| US20070280690A1 (en) * | 2006-06-02 | 2007-12-06 | Fujitsu Limited | System and Method for Managing Power in an Optical Network |
-
2005
- 2005-09-21 KR KR1020077008930A patent/KR20070057965A/ko not_active Withdrawn
- 2005-09-21 BR BRPI0515546-0A patent/BRPI0515546A/pt not_active IP Right Cessation
- 2005-09-21 AU AU2005286701A patent/AU2005286701A1/en not_active Abandoned
- 2005-09-21 MX MX2007003342A patent/MX2007003342A/es not_active Application Discontinuation
- 2005-09-21 TW TW094132617A patent/TW200621232A/zh unknown
- 2005-09-21 CA CA002580852A patent/CA2580852A1/en not_active Abandoned
- 2005-09-21 JP JP2007532665A patent/JP2008513508A/ja active Pending
- 2005-09-21 EP EP05814906A patent/EP1809294A4/en not_active Withdrawn
- 2005-09-21 WO PCT/US2005/033980 patent/WO2006034402A2/en not_active Ceased
- 2005-09-21 US US11/233,224 patent/US7709518B2/en not_active Expired - Fee Related
- 2005-09-21 CN CNA200580038882XA patent/CN101083985A/zh active Pending
-
2007
- 2007-03-19 IL IL182025A patent/IL182025A0/en unknown
- 2007-03-20 ZA ZA200702350A patent/ZA200702350B/xx unknown
-
2010
- 2010-03-05 US US12/718,366 patent/US8314134B2/en not_active Expired - Fee Related
-
2012
- 2012-10-16 US US13/652,878 patent/US8524756B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101245062B1 (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| AU2015355839B2 (en) | Heterocyclic derivatives and use thereof | |
| DE60219698T2 (de) | Glukokinase beeinflussende Verbindungen | |
| AU2005321609B2 (en) | Fused bicyclic carboxamide derivatives for use as CXCR2 inhibitors in the treatment of inflammation | |
| KR20070057965A (ko) | 염증 및 면역 관련 용도를 위한 화합물 | |
| WO2002051397A1 (en) | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same | |
| JP2009530409A (ja) | 炎症及び免疫関連使用用のベンゾイミダゾリル−ピリジン化合物 | |
| MX2007009592A (es) | Terapia de combinacion. | |
| CN102459158B (zh) | 新的酰胺和脒衍生物和其用途 | |
| DK3009426T3 (en) | 4-ALKYNYL-IMIDAZOLE DERIVATIVE AND MEDICINE COMPREHENSIVE AS AN ACTIVE INGREDIENT | |
| MX2010013058A (es) | Derivado de benceno o tiofeno y su uso como inhibidor de proteina 1 de adhesion vascular. | |
| JP2006522748A5 (enExample) | ||
| TW200524575A (en) | Biaryl linked hydroxamates: preparation and pharmaceutical applications | |
| IL234559A (en) | Heterocyclic compounds | |
| AU2007227210A1 (en) | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses | |
| SK6262000A3 (en) | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors | |
| JP2015506347A5 (enExample) | ||
| JP2010535214A5 (enExample) | ||
| AU2019319745B2 (en) | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | |
| CN101208089A (zh) | 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂 | |
| CA2377771A1 (en) | Heterocyclic compounds and medical use thereof | |
| JP2013530179A (ja) | 呼吸器合胞体ウイルス（ｒｓｖ）感染の処置に使用するためのウレイド−ピラゾール誘導体 | |
| US20140275016A1 (en) | N-Acyl-N'-(pyridin-2-yl) Ureas and Analogs Exhibiting Anti-Cancer and Anti-Proliferative Activities | |
| JP4669839B2 (ja) | ジフェニルピリジン誘導体、その製造法および治療用途 | |
| AU2010308277A1 (en) | Indazole and pyrazolopyridine compounds as CCR1 receptor antagonists |